This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes
by Zacks Equity Research
With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check.
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues
by Zacks Equity Research
IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Hold IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket
by Zacks Equity Research
IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.
Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 4.09% and 0.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of 23.19% and 0.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Waters (WAT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Waters (WAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDXX Gears Up for Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' third-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
Are Options Traders Betting on a Big Move in IDEXX Laboratories (IDXX) Stock?
by Nandini Tamret
Investors need to pay close attention to IDEXX Laboratories (IDXX) stock based on the movements in the options market lately.
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Why Is Idexx (IDXX) Up 0.9% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Do Options Traders Know Something About IDEXX (IDXX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to IDEXX (IDXX) stock based on the movements in the options market lately.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idexx Laboratories (IDXX) Lags Q2 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of -14.98% and 0.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Baxter International, Henry Schein and IDEXX Laboratories
by Zacks Equity Research
Baxter International, Henry Schein and IDEXX Laboratories are included in this Analyst Blog.
What's in Store for These 3 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
MedTech companies' quarterly results are likely to be strong on a sequential basis. Let's see how BAX, HSIC and IDXX are placed ahead of their earnings releases.
Unlocking Q2 Potential of Idexx (IDXX): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Idexx (IDXX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.